Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Adam M. Brufsky"'
Autor:
Ami N. Shah, Bora Lim, Monica M. Mita, Elizabeth Mauer, Kayla V. Layng, Calvin Chao, Adam M. Brufsky
Publikováno v:
Cancer Research. 83:P2-23
Background: Recent studies suggest differences in outcomes among patients (pts) with metastatic breast cancer (MBC) treated with abemaciclib, ribociclib, or palbociclib, but whether these differences have a genomic basis is unknown. Here, we utilize
Autor:
Heather A. Parsons, Timothy Blewett, Xiangying Chu, Sainetra Sridhar, Katheryn Santos, Kan Xiong, Vandana Abramson, Ashka Patel, Ju Cheng, Adam M. Brufsky, Justin Rhoades, Jeremy Force, Ruolin Liu, Tiffany A. Traina, Lisa Carey, Mothaffar Rimawi, Ahmed Elkhanany, Vered Stearns, Jennifer M. Specht, Harold Burstein, Antonio C. Wolff, Eric Winer, Nabihah Tayob, Ian Krop, Todd Golub, Erica L. Mayer, Viktor Adalsteinsson
Publikováno v:
Cancer Research. 83:PD11-06
Background. Patients (pts) with early triple negative breast cancer (eTNBC) are at increased risk of breast cancer recurrence and death. Recent studies have focused on escalation of therapy, with current treatment standard of at least five drugs –
Autor:
Adam M. Brufsky, Martine C. Maculaitis, Lewis Kopenhafer, Patrick Olsen, Ashley S. Cha, Lillian Shahied Arruda, Wendy Heck, Samantha K. Kurosky
Publikováno v:
Cancer Research. 83:P4-07
Background: Despite demonstrated clinical benefits of first line (1L) cyclin-dependent kinases 4/6 inhibitors (CDK4/6i) and their preferred status in the NCCN guidelines, many appropriate patients with hormone receptor positive (HR+)/human epidermal
Autor:
Katherine K. Clifton, Shana N. Thomas, Jingqin Luo, Jing Xi, Nusayba A. Bagegni, Foluso O. Ademuyiwa, Rama Suresh, Ashley Frith, Andrew A. Davis, Ron Bose, Katherine Weilbaecher, Whitney L. Hensing, Timothy Pluard, Massimo Cristofanilli, Hyo S. Han, Adam M. Brufsky, Kevin Kalinsky, Shom Goel, Seth A. Wander, Lindsay L. Peterson, Cynthia Ma
Publikováno v:
Cancer Research. 83:PD13-09
Background: CDK4/6 inhibitors (CDK4/6i) paired with endocrine therapy (ET) are considered first-line (1L) therapy for patients (pts) with HR+ HER2- advanced breast cancer (aBC). A minority of pts will demonstrate primary resistance to CDK4/6i, as cha
Autor:
Giuseppe Viale, Mark Basik, Naoki Niikura, Eriko Tokunaga, Sara Brucker, Frédérique Penault-Llorca, Naoki Hayashi, Joo Hyuk Sohn, Rita Teixeira de Sousa, Adam M. Brufsky, Ciara S. O’Brien, Fernando Schmitt, Gavin Higgins, Della Varghese, Gareth D. James, Akira Moh, Andrew Livingston, Victoria de Giorgio-Miller
Publikováno v:
Cancer Research. 83:HER2-15
Background: About 60% of breast cancers (BCs) traditionally categorized as HER2 negative (HER2-neg; immunohistochemistry [IHC] 0, IHC 1+ or IHC 2+/in situ hybridization [ISH]–) express low levels of HER2 (HER2-low; IHC 1+ or IHC 2+/ISH–; Schettin
Autor:
Charles E. Geyer, Jr, Gong Tang, Priya Rastogi, Vicente Valero, Stephen K. Chia, Erin F. Cobain, Elias Obeid, David B. Page, Andrew S. Poklepovic, William J. Irvin, Jr., Adam M. Brufsky, Irene L. Wapnir, Jennifer M. Suga, Eleftherios (Terry) Mamounas, Norman Wolmark
Publikováno v:
Cancer Research. 83:OT2-16
Background: The CLEOPATRA trial established trastuzumab, pertuzumab and a taxane (THP) as a standard of care for first line metastatic, HER2-positve breast cancer with median progression-free survival (PFS) of 18.7 months and median OS of 57 months.
Autor:
Hiba Abujaradeh, Susan Mazanec, Susan M. Sereika, Adam M. Brufsky, Catherine M. Bender, Mary C. Connolly, Margaret Q. Rosenzweig
Publikováno v:
Cancer Research. 83:P6-08
Introduction: Social support (SS) is predictive of symptom distress among patients with breast cancer (BC) during the treatment and post-treatment phases. There is evidence of racial and economic disparities in SS seen among patients with cancer. Lit
Autor:
Steffi Oesterreich, Adrian V. Lee, Peter C. Lucas, Esther Elishaev, Adam M. Brufsky, Ronald L. Hamilton, Jose P. Leone, Jens-Uwe Blohmer, Carsten Denkert, Maria M. Karsten, Kurt R. Weiss, Rohit Bhargava, Michelle M. Boisen, Rebecca J. Watters, Amir Bahreini, Ethan S. Sokol, Ryan J. Hartmaier, Nolan Priedigkeit, Ahmed Basudan
Table S1. Clinicopathological characteristics and sample distribution by site Table S2. Primers/probes design for ddPCR (ESR1, EIF2C, AP3P1) Table S3. Raw nanoString counts Table S4. Normalized copy number calls (ER+ samples) Table S5. Normalized cop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d9e59f5e3d10c1d4f9b6cf3550a23c1
https://doi.org/10.1158/1541-7786.22513387
https://doi.org/10.1158/1541-7786.22513387
Autor:
Steffi Oesterreich, Adrian V. Lee, Peter C. Lucas, Esther Elishaev, Adam M. Brufsky, Ronald L. Hamilton, Jose P. Leone, Jens-Uwe Blohmer, Carsten Denkert, Maria M. Karsten, Kurt R. Weiss, Rohit Bhargava, Michelle M. Boisen, Rebecca J. Watters, Amir Bahreini, Ethan S. Sokol, Ryan J. Hartmaier, Nolan Priedigkeit, Ahmed Basudan
Figure S1: Genomic organization of ESR1 nanoString probes Figure S2: Correlation of ESR1 amplification with mRNA expression Figure S3: ESR1 copy number status in ER+ primary-metastasis pairs Figure S4: Oncoprint visualization of copy number alteratio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fb4ca70d3e077735a7368e8ee70c5eb
https://doi.org/10.1158/1541-7786.22513390.v1
https://doi.org/10.1158/1541-7786.22513390.v1
Autor:
Robert E. Ferrell, Adam M. Brufsky, Stephen D. Meriney, Eleanor Feingold, Elizabeth C. Lawrence, Mark A. Kimak, Diana Huang, Jenny M. Karlsson, Diana Campbell, Sarah E. Noon, Shelley Perschke, Kelly Z. Knickelbein, Catherine J. Baty, David N. Finegold
Purpose: Secondary lymphedema is a frequent complication of breast cancer associated with surgery, chemotherapy, or radiation following breast cancer treatment. The potential contribution of genetic susceptibility to risk of developing secondary lymp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e7d3c0951a98c5a748fc3893da4fb48
https://doi.org/10.1158/1078-0432.c.6520118
https://doi.org/10.1158/1078-0432.c.6520118